1
|
Maisano D, Mimmi S, Dattilo V, Marino F, Gentile M, Vecchio E, Fiume G, Nisticò N, Aloisio A, de Santo MP, Desiderio G, Musolino V, Nucera S, Sbrana F, Andò S, Ferrero S, Morandi A, Bertoni F, Quinto I, Iaccino E. A novel phage display based platform for exosome diversity characterization. NANOSCALE 2022; 14:2998-3003. [PMID: 35141731 DOI: 10.1039/d1nr06804k] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
We present an innovative approach allowing the identification, isolation, and molecular characterization of disease-related exosomes based on their different antigenic reactivities. The designed strategy could be immediately translated into any disease in which exosomes are involved. The identification of specific markers and their subsequent association with exosome subtypes, together with the possibility to engineer target-guided exosome-like particles, could represent the key for the effective adoption of exosomes in clinical practice.
Collapse
Affiliation(s)
- Domenico Maisano
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Selena Mimmi
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Vincenzo Dattilo
- Genetics Units, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Fabiola Marino
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | | | - Eleonora Vecchio
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Giuseppe Fiume
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Nancy Nisticò
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Annamaria Aloisio
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | | | - Giovanni Desiderio
- CNR/Nanotec, Physics Department, University of Calabria, Rende, CS, Italy
| | - Vincenzo Musolino
- IRC-FSH Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy
| | - Saverio Nucera
- IRC-FSH Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy
| | | | | | - Simone Ferrero
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Turin, Italy
| | - Andrea Morandi
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
| | - Francesco Bertoni
- IOR, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Enrico Iaccino
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| |
Collapse
|
2
|
An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach. Cancers (Basel) 2021; 13:cancers13122893. [PMID: 34207773 PMCID: PMC8226720 DOI: 10.3390/cancers13122893] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 06/04/2021] [Accepted: 06/08/2021] [Indexed: 02/07/2023] Open
Abstract
Simple Summary Lymphoma research is a paradigm of integrating basic and applied research within the fields of molecular marker-based diagnosis and therapy. In recent years, major advances in next-generation sequencing have substantially improved the understanding of the genomics underlying diffuse large B-cell lymphoma (DLBCL), the most frequent type of B-cell lymphoma. This review addresses the various approaches that have helped unveil the biology and intricate alterations in this pathology, from cell lines to more sophisticated last-generation experimental models, such as organoids. We also provide an overview of the most recent findings in the field, their potential relevance for designing targeted therapies and the corresponding applicability to personalized medicine. Abstract Lymphoma research is a paradigm of the integration of basic and clinical research within the fields of diagnosis and therapy. Clinical, phenotypic, and genetic data are currently used to predict which patients could benefit from standard treatment. However, alternative therapies for patients at higher risk from refractoriness or relapse are usually empirically proposed, based on trial and error, without considering the genetic complexity of aggressive B-cell lymphomas. This is primarily due to the intricate mosaic of genetic and epigenetic alterations in lymphomas, which are an obstacle to the prediction of which drug will work for any given patient. Matching a patient’s genes to drug sensitivity by directly testing live tissues comprises the “precision medicine” concept. However, in the case of lymphomas, this concept should be expanded beyond genomics, eventually providing better treatment options for patients in need of alternative therapeutic approaches. We provide an overview of the most recent findings in diffuse large B-cell lymphomas genomics, from the classic functional models used to study tumor biology and the response to experimental treatments using cell lines and mouse models, to the most recent approaches with spheroid/organoid models. We also discuss their potential relevance and applicability to daily clinical practice.
Collapse
|
3
|
Aloisio A, Nisticò N, Mimmi S, Maisano D, Vecchio E, Fiume G, Iaccino E, Quinto I. Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy. Viruses 2021; 13:649. [PMID: 33918836 PMCID: PMC8070105 DOI: 10.3390/v13040649] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 04/04/2021] [Accepted: 04/07/2021] [Indexed: 02/06/2023] Open
Abstract
Receptor tyrosine kinases (RTKs) regulate critical physiological processes, such as cell growth, survival, motility, and metabolism. Abnormal activation of RTKs and relative downstream signaling is implicated in cancer pathogenesis. Phage display allows the rapid selection of peptide ligands of membrane receptors. These peptides can target in vitro and in vivo tumor cells and represent a novel therapeutic approach for cancer therapy. Further, they are more convenient compared to antibodies, being less expensive and non-immunogenic. In this review, we describe the state-of-the-art of phage display for development of peptide ligands of tyrosine kinase membrane receptors and discuss their potential applications for tumor-targeted therapy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Ileana Quinto
- Correspondence: (A.A.); (I.Q.): Tel.: +39-0961-3694057 (I.Q.)
| |
Collapse
|
4
|
Mashima K, Azuma M, Fujiwara K, Inagaki T, Oh I, Ikeda T, Umino K, Nakano H, Morita K, Sato K, Minakata D, Yamasaki R, Ashizawa M, Yamamoto C, Fujiwara SI, Hatano K, Ohmine K, Muroi K, Ohno N, Kanda Y. Differential Localization and Invasion of Tumor Cells in Mouse Models of Human and Murine Leukemias. Acta Histochem Cytochem 2020; 53:43-53. [PMID: 32624629 PMCID: PMC7322163 DOI: 10.1267/ahc.19035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Accepted: 04/13/2020] [Indexed: 12/19/2022] Open
Abstract
Leukemias are refractory hematopoietic malignancies, for which the development of new therapeutic agents requires in vivo studies using tumor-bearing mouse models. Although several organs are commonly examined in such studies to evaluate the disease course, the effectiveness of interventions and the localization of tumor cells in the affected organs are still unclear. In this study, we histologically examined the distribution of leukemia cells in several organs using two leukemic mouse models produced by the administration of two cell lines (THP-1, a human myelomonocytic leukemia, and A20, a mouse B cell leukemia/lymphoma) to severe immunodeficient mice. Survival of the mice depended on the tumor burden. Although A20 and THP-1 tumor cells massively infiltrated the parenchyma of the liver and spleen at 21 days after transplantation, A20 cells were hardly found in connective tissues in Glisson’s capsule in the liver as compared with THP-1 cells. In the bone marrow, there was more severe infiltration of A20 cells than THP-1 cells. THP-1 and A20 cells were widely spread in the lungs, but were rarely observed in the small intestine. These findings suggest that each leukemia model has a unique localization of tumor cells in several affected organs, which could critically affect the disease course and the efficacy of therapeutic agents, including cellular immunotherapies.
Collapse
Affiliation(s)
- Kiyomi Mashima
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Morio Azuma
- Division of Molecular Pharmacology, Department of Pharmacology, Jichi Medical University
| | - Ken Fujiwara
- Division of Histology and Cell Biology, Department of Anatomy, Jichi Medical University
| | - Takeshi Inagaki
- Division of Forensic Medicine, Department of Anatomy, Jichi Medical University
| | - Iekuni Oh
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Takashi Ikeda
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Kento Umino
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Hirofumi Nakano
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Kaoru Morita
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Kazuya Sato
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Daisuke Minakata
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Ryoko Yamasaki
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Masahiro Ashizawa
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Chihiro Yamamoto
- Division of Hematology, Department of Medicine, Jichi Medical University
| | | | - Kaoru Hatano
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Ken Ohmine
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Kazuo Muroi
- Division of Hematology, Department of Medicine, Jichi Medical University
| | - Nobuhiko Ohno
- Division of Histology and Cell Biology, Department of Anatomy, Jichi Medical University
| | - Yoshinobu Kanda
- Division of Hematology, Department of Medicine, Jichi Medical University
| |
Collapse
|
5
|
Detection of chronic lymphocytic leukemia subpopulations in peripheral blood by phage ligands of tumor immunoglobulin B cell receptors. Leukemia 2020; 35:610-614. [PMID: 32483301 PMCID: PMC7862058 DOI: 10.1038/s41375-020-0885-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 05/15/2020] [Accepted: 05/21/2020] [Indexed: 01/25/2023]
|
6
|
Kulkarni S, Pandey A, Mutalik S. Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies. Drug Discov Today 2020; 25:160-167. [DOI: 10.1016/j.drudis.2019.10.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2019] [Revised: 09/26/2019] [Accepted: 10/01/2019] [Indexed: 12/13/2022]
|
7
|
Molecular modelling of epitopes recognized by neoplastic B lymphocytes in Chronic Lymphocytic Leukemia. Eur J Med Chem 2019; 185:111838. [PMID: 31718942 DOI: 10.1016/j.ejmech.2019.111838] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 10/29/2019] [Accepted: 10/30/2019] [Indexed: 12/22/2022]
Abstract
Identification of epitopes recognized by tumour B cells could provide insights into the molecular mechanisms of B cell tumorigenesis through aberrant B cell receptor (BCR) signalling. Here, we analysed the structure of eleven peptides binders of BCRs expressed in Chronic Lymphocytic Leukemia (CLL) patients in order to identify the chemical features required for cross-reactive binding to different CLL clonotypes. Four cross-reactive (CR) and seven no-cross-reactive (NCR) peptides were analysed by means of GRID molecular interaction fields, ligand-based pharmacophore and 3D-QSAR approaches. Based on pharmacophore model, two peptides were generated by specific amino acids substitutions of the parental NCR peptides; these new peptides resumed the common chemical features of CR peptides and bound the CLL BCR clonotypes recognized by CR peptides and parental NCR peptides. Thus, our computational approach guided the pharmacophore modelling of CR peptides. In perspective, peptide binders of CLL BCR clonotypes could represent a powerful tool for computational modelling of epitopes recognized by tumour B cells clones.
Collapse
|
8
|
Mangini M, Iaccino E, Mosca MG, Mimmi S, D'Angelo R, Quinto I, Scala G, Mariggiò S. Peptide-guided targeting of GPR55 for anti-cancer therapy. Oncotarget 2018; 8:5179-5195. [PMID: 28029647 PMCID: PMC5354900 DOI: 10.18632/oncotarget.14121] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 11/21/2016] [Indexed: 12/21/2022] Open
Abstract
Expression of the lysophosphatidylinositol receptor GPR55 correlates with invasive potential of metastatic cells and bone metastasis formation of different types of tumors. These findings suggest a role for GPR55 signaling in cancer progression, including in lymphoproliferative diseases. Here, we screened a M13-phage-displayed random library using the bait of HEK293 cells that heterologously expressed full-length HA-GPR55. We selected a set of phagotopes that carried 7-mer insert peptides flanked by a pair of cysteine residues, which resulted in cyclized peptides. Sequencing of selected phagotopes dictated the primary structure for the synthetic FITC-labeled peptide P1, which was analyzed for binding specificity to immunoprecipitated HA-GPR55, and to endogenously expressed GPR55, using cells interfered or not for GPR55, as well as for co-localization imaging with HA-GPR55 at the membrane level. The peptide P1 stimulated GPR55 endocytosis and inhibited GPR55-dependent proliferation of EHEB and DeFew cells, two human B-lymphoblastoid cell lines. Our data support the potential therapeutic application of peptide ligands of GPR55 for targeting and inhibiting growth of neoplastic cells, which overexpress GPR55 and are dependent on GPR55 signaling for their proliferation.
Collapse
Affiliation(s)
- Maria Mangini
- Institute of Protein Biochemistry, National Research Council, Naples, Italy
| | - Enrico Iaccino
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | | | - Selena Mimmi
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - Rosa D'Angelo
- Institute of Protein Biochemistry, National Research Council, Naples, Italy
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - Giuseppe Scala
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - Stefania Mariggiò
- Institute of Protein Biochemistry, National Research Council, Naples, Italy
| |
Collapse
|
9
|
Torino E, Auletta L, Vecchione D, Orlandella FM, Salvatore G, Iaccino E, Fiorenza D, Grimaldi AM, Sandomenico A, Albanese S, Sarnataro D, Gramanzini M, Palmieri C, Scala G, Quinto I, Netti PA, Salvatore M, Greco A. Multimodal imaging for a theranostic approach in a murine model of B-cell lymphoma with engineered nanoparticles. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2018; 14:483-491. [DOI: 10.1016/j.nano.2017.11.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 11/02/2017] [Accepted: 11/13/2017] [Indexed: 11/25/2022]
|
10
|
Pradhan P, Leleux J, Liu J, Roy K. A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model. JCI Insight 2017; 2:92522. [PMID: 29202455 DOI: 10.1172/jci.insight.92522] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Accepted: 10/17/2017] [Indexed: 12/16/2022] Open
Abstract
Despite initial remission after successful treatments, B lymphoma patients often encounter relapses and resistance causing high mortality. Thus, there is a need to develop therapies that prevent relapse by providing long-term protection and, ultimately, lead to functional cure. In this study, our goal was to develop a simple, clinically relevant, and easily translatable therapeutic vaccine that provides durable immune protection against aggressive B cell lymphoma and identify critical immune biomarkers that are predictive of long-term survival. In a delayed-treatment, aggressive, murine model of A20 B lymphoma that mimics human diffuse large B cell lymphoma, we show that therapeutic A20 lysate vaccine adjuvanted with an NKT cell agonist, α-galactosylceramide (α-GalCer), provides long-term immune protection against lethal tumor challenges and the antitumor immunity is primarily CD8 T cell dependent. Using experimental and computational methods, we demonstrate that the initial strength of germinal center reaction and the magnitude of class-switching into a Th1 type humoral response are the best predictors for the long-term immunity of B lymphoma lysate vaccine. Our results not only provide fundamentally insights for successful immunotherapy and long-term protection against B lymphomas, but also present a simple, therapeutic vaccine that can be translated easily due to the facile and inexpensive method of preparation.
Collapse
|
11
|
Iaccino E, Mimmi S, Dattilo V, Marino F, Candeloro P, Di Loria A, Marimpietri D, Pisano A, Albano F, Vecchio E, Ceglia S, Golino G, Lupia A, Fiume G, Quinto I, Scala G. Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. Mol Cancer 2017; 16:159. [PMID: 29029605 PMCID: PMC5640902 DOI: 10.1186/s12943-017-0730-8] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 10/09/2017] [Indexed: 12/18/2022] Open
Abstract
Tumor-derived exosomes (TDEs) play a pivotal role in tumor establishment and progression, and are emerging biomarkers for tumor diagnosis in personalized medicine. To date, there is a lack of efficient technology platforms for exosome isolation and characterization. Multiple myeloma (MM) is an incurable B-cell malignancy due to the rapid development of drug-resistance. MM-released exosomes express the immunoglobulin B-cell receptor (Ig-BCR) of the tumor B-cells, which can be targeted by Idiotype-binding peptides (Id-peptides). In this study, we analyzed the production of MM-released exosomes in the murine 5T33MM multiple myeloma model as biomarkers of tumor growth. To this end, we selected Id-peptides by screening a phage display library using as bait the Ig-BCR expressed by 5T33MM cells. By FACS, the FITC-conjugated Id-peptides detected the MM-released exosomes in the serum of 5T33MM-engrafted mice, levels of which are correlated with tumor progression at an earlier time point compared to serum paraprotein. These results indicate that Id-peptide-based recognition of MM-released exosomes may represent a very sensitive diagnostic approach for clinical evaluation of disease progression.
Collapse
Affiliation(s)
- Enrico Iaccino
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy.
| | - Selena Mimmi
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Vincenzo Dattilo
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Fabiola Marino
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Patrizio Candeloro
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Antonio Di Loria
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Danilo Marimpietri
- Stem Cell and Cellular Therapy Laboratory, G. Gaslini Institute, Genoa, Italy
| | - Antonio Pisano
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Francesco Albano
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Eleonora Vecchio
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Simona Ceglia
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Gaetanina Golino
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Antonio Lupia
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Giuseppe Fiume
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy.
| | - Giuseppe Scala
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia,", Catanzaro, Italy
| |
Collapse
|
12
|
Cardoso FM, Tomkova M, Petrovajova D, Bubanova M, Ragac O, Hornakova T. New and cost effective cell-based assay for Dialyzed Leukocyte Extract (DLE)-induced Jurkat cells proliferation under azathioprine treatment. J Pharm Biomed Anal 2017; 138:100-108. [PMID: 28189890 DOI: 10.1016/j.jpba.2017.01.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 01/23/2017] [Accepted: 01/26/2017] [Indexed: 11/16/2022]
Abstract
The human Dialyzed Leukocyte Extract (DLE) is a heterogeneous mix of oligopeptides of <10kDa, extracted from leukocytes of healthy donors. There is significant clinical evidence of improvement using DLE during treatment of allergies, cancer,immunodeficiencies, and in mycotic and viral infections. Nevertheless, the DLE exact nature and mechanism of action have been elusive for more than 50 years. DLE biological activity testing is necessary in DLE production and quality control. Both in vitro and in vivo assays exist: E-rosette test, induction of delayed type hypersensitivity in mice, leukocyte migration and IFN-γ secretion. The animal-origin materials and in vivo assays convey a considerable logistic, ethic and economic burden, meanwhile the available in vitro assays have been reported with limited reproducibility and sometimes contradictory results. Here we are reporting a new DLE biological activity cell-based assay. The A20 and Jurkat cell lines were treated with (+Aza) or without (-Aza) azathioprine, DLE (+DLE) or both (+Aza/+DLE). After 72h, the cell proliferation was analyzed by the MTT or BrdU incorporation assays. In +Aza/+DLE treated cells, we observed a significant higher proliferation, when compared with +Aza/-DLE. In the absence of Aza, cells did not present any proliferation difference between -DLE or +DLE treatments. Both assays, MTT and BrdU showed similar results, being the MTT test more cost effective and we select it for validation as DLE biological assay using Jurkat cells only. We tested three different lyophilized DLE batches and we found consistent results with acceptable assay reproducibility and linearity. The DLE capacity for rescuing Jurkat cell proliferation during +Aza treatment was consistent using different liquid and lyophilized DLE batches, presenting also consistent chromatographic profiles. Finally, DLE treatment in Jurkat cells did not result into significant IL-2 of IFN-γ secretion, and known lymphocyte proliferative drugs failed to rescue Jurkat cells viability in presence of +Aza, as +DLE treatment did in our MTT assay. In conclusion, our new cell-based MTT assay has excellent DLE biological activity consistency, robustness and is cost effective, presenting important advantages over previous DLE activity in vitro and in vivo assays.
Collapse
Affiliation(s)
- F M Cardoso
- R&D Department, Imuna Pharm a. s., Jarková 17, 082 22 Šarišské Michaľany, Slovak Republic.
| | - M Tomkova
- R&D Department, Imuna Pharm a. s., Jarková 17, 082 22 Šarišské Michaľany, Slovak Republic
| | - D Petrovajova
- R&D Department, Imuna Pharm a. s., Jarková 17, 082 22 Šarišské Michaľany, Slovak Republic
| | - M Bubanova
- R&D Department, Imuna Pharm a. s., Jarková 17, 082 22 Šarišské Michaľany, Slovak Republic
| | - O Ragac
- R&D Department, Imuna Pharm a. s., Jarková 17, 082 22 Šarišské Michaľany, Slovak Republic
| | - T Hornakova
- R&D Department, Imuna Pharm a. s., Jarková 17, 082 22 Šarišské Michaľany, Slovak Republic; Olomouc University Social Health Institute (OUSHI), Univerzitní 22, 771 11 Olomouc, Czech Republic
| |
Collapse
|
13
|
Gheran CV, Voicu SN, Rigaux G, Callewaert M, Chuburu F, Dinischiotu A. Biological effects induced by Gadolinium nanoparticles on Lymphocyte A20 cell line. THE EUROBIOTECH JOURNAL 2017. [DOI: 10.24190/issn2564-615x/2017/01.09] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Abstract
Gadolinium nanoparticles (GdNPs) are potential agents for MRI of lymph nodes. The aim of this study was to evaluate the in vitro effects of 1 μM, 2.5 μM and 5 μM of GdDOTA⊂CS-TPP/HA and GdDOTP⊂CS-TPP/HA NPs on A20 lymphocyte cells exposed for 6 and 24 hours. The total cellular biomass (SRB), lactate dehydrogenase activity (LDH) and oxidative stress parameters, such as reactive oxygen species generation (ROS), reduced glutathione (GSH), malondialdehyde (MDA) and advanced oxidation protein products (AOPP) were analyzed by spectrophotometric and fluorimetric methods. After cells exposure to 1 μM, 2.5 μM and 5 μM of GdDOTP⊂CS-TPP/HA NPs their viability decreased in a time- and dose-dependent manner, whereas for GdDOTA⊂CS-TPP/HA no significant changes were noticed. Both NPs formulations in doses of 1 μM, 2.5 μM, 5 μM did not affect the plasma membrane at each time point tested. The levels of ROS, MDA and AOPP increased proportionally with the concentration and exposure time. GSH concentration decreased significantly for all doses of both NPs tested. Taken together our data suggest that, GdDOTP⊂CS-TPP/HA and GdDOTA⊂CS-TPP/HA NPs induced oxidative stress in A20 lymphocyte cells which was counteracted by the cells antioxidant defense system to a certain extend.
Collapse
Affiliation(s)
- Cecilia Virginia Gheran
- Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, Bucharest , Romania
| | - Sorina Nicoleta Voicu
- Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, Bucharest , Romania
- Department of Pharmacy, Faculty of Pharmacy, Titu Maiorescu University, Bucharest , Romania
| | - Guillaume Rigaux
- Institut de Chimie Moleculaire de Reims, CNRS UMR 7312, Universite de Reims Champagne-Ardenne URCA, 51685 Reims Cedex 2, France
| | - Maite Callewaert
- Institut de Chimie Moleculaire de Reims, CNRS UMR 7312, Universite de Reims Champagne-Ardenne URCA, 51685 Reims Cedex 2, France
| | - Francoise Chuburu
- Institut de Chimie Moleculaire de Reims, CNRS UMR 7312, Universite de Reims Champagne-Ardenne URCA, 51685 Reims Cedex 2, France
| | - Anca Dinischiotu
- Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, Bucharest , Romania
| |
Collapse
|
14
|
Calzada V, Moreno M, Newton J, González J, Fernández M, Gambini JP, Ibarra M, Chabalgoity A, Deutscher S, Quinn T, Cabral P, Cerecetto H. Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept. Bioorg Med Chem 2016; 25:1163-1171. [PMID: 28089349 DOI: 10.1016/j.bmc.2016.12.026] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2016] [Revised: 12/05/2016] [Accepted: 12/19/2016] [Indexed: 11/26/2022]
Abstract
Aptamers are single-stranded oligonucleotides that recognize molecular targets with high affinity and specificity. Aptamer that selectively bind to the protein tyrosine kinase-7 (PTK7) receptor, overexpressed on many cancers, has been labelled as probes for molecular imaging of cancer. Two new PTK7-targeting aptamer probes were developed by coupling frameworks from the fluorescent dye AlexaFluor647 or the 6-hydrazinonicotinamide (HYNIC) chelator-labelled to 99mTc. The derivatizations via a 5'-aminohexyl terminal linker were done at room temperature and under mild buffer conditions. Physicochemical and biological controls for both imaging agents were performed verifying the integrity of the aptamer-conjugates by HPLC. Recognition of melanoma (B16F1) and lymphoma (A20) mouse cell lines by the aptamer was studied using cell binding, flow cytometry and confocal microscopy. Finally, in vivo imaging studies in tumour-bearing mice were performed. The new probes were able to bind to melanoma and lymphoma cell lines in vitro, the in vivo imaging in tumour-bearing mice showed different uptake behaviours showing for the fluorescent conjugate good uptake by B cell lymphoma while the radiolabelled conjugate did not display tumour uptake due to its high extravascular distribution, and both showed rapid clearance properties in tumour-bearing mice.
Collapse
Affiliation(s)
- Victoria Calzada
- Área de Radiofarmacia-Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, 11400 Montevideo, Uruguay
| | - María Moreno
- Departamento de Desarrollo Biotecnológico-Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
| | - Jessica Newton
- Department of Biochemistry, University of Missouri, Columbia, MO, USA; Harry S Truman Veterans' Administration Hospital, Columbia, MO, USA
| | - Joel González
- Laboratorio de Experimentación Animal-Centro de Investigaciones Nucleares, Facultad de Ciencias-Universidad de la República, Montevideo, Uruguay
| | - Marcelo Fernández
- Laboratorio de Experimentación Animal-Centro de Investigaciones Nucleares, Facultad de Ciencias-Universidad de la República, Montevideo, Uruguay
| | - Juan Pablo Gambini
- Centro de Medicina Nuclear-Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay
| | - Manuel Ibarra
- Centro de Evaluación de Biodisponibilidad y Bioequivalencia de Medicamentos, Universidad de la República, Montevideo, Uruguay
| | - Alejandro Chabalgoity
- Departamento de Desarrollo Biotecnológico-Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
| | - Susan Deutscher
- Department of Biochemistry, University of Missouri, Columbia, MO, USA; Harry S Truman Veterans' Administration Hospital, Columbia, MO, USA
| | - Thomas Quinn
- Department of Biochemistry, University of Missouri, Columbia, MO, USA; Harry S Truman Veterans' Administration Hospital, Columbia, MO, USA
| | - Pablo Cabral
- Área de Radiofarmacia-Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, 11400 Montevideo, Uruguay
| | - Hugo Cerecetto
- Área de Radiofarmacia-Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, 11400 Montevideo, Uruguay.
| |
Collapse
|
15
|
Martucci NM, Migliaccio N, Ruggiero I, Albano F, Calì G, Romano S, Terracciano M, Rea I, Arcari P, Lamberti A. Nanoparticle-based strategy for personalized B-cell lymphoma therapy. Int J Nanomedicine 2016; 11:6089-6101. [PMID: 27895482 PMCID: PMC5117954 DOI: 10.2147/ijn.s118661] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
B-cell lymphoma is associated with incomplete response to treatment, and the development of effective strategies targeting this disease remains challenging. A new personalized B-cell lymphoma therapy, based on a site-specific receptor-mediated drug delivery system, was developed in this study. Specifically, natural silica-based nanoparticles (diatomite) were modified to actively target the antiapoptotic factor B-cell lymphoma/leukemia 2 (Bcl2) with small interfering RNA (siRNA). An idiotype-specific peptide (Id-peptide) specifically recognized by the hypervariable region of surface immunoglobulin B-cell receptor was exploited as a homing device to ensure specific targeting of lymphoma cells. Specific nanoparticle uptake, driven by the Id-peptide, was evaluated by flow cytometry and confocal microscopy and was increased by approximately threefold in target cells compared with nonspecific myeloma cells and when a random control peptide was used instead of Id-peptide. The specific internalization efficiency was increased by fourfold when siRNA was also added to the modified nanoparticles. The modified diatomite particles were not cytotoxic and their effectiveness in downregulation of gene expression was explored using siRNA targeting Bcl2 and evaluated by quantitative real-time polymerase chain reaction and Western blot analyses. The resulting gene silencing observed is of significant biological importance and opens new possibilities for the personalized treatment of lymphomas.
Collapse
Affiliation(s)
- Nicola M Martucci
- Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples
| | - Nunzia Migliaccio
- Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples
| | - Immacolata Ruggiero
- Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples
| | - Francesco Albano
- Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro
| | - Gaetano Calì
- Institute of Endocrinology and Molecular Oncology
| | - Simona Romano
- Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples
| | - Monica Terracciano
- Institute for Microelectronics and Microsystems, National Research Council, Naples, Italy
| | - Ilaria Rea
- Institute for Microelectronics and Microsystems, National Research Council, Naples, Italy
| | - Paolo Arcari
- Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples
| | - Annalisa Lamberti
- Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples
| |
Collapse
|
16
|
Mimmi S, Vecchio E, Iaccino E, Rossi M, Lupia A, Albano F, Chiurazzi F, Fiume G, Pisano A, Ceglia S, Pontoriero M, Golino G, Tassone P, Quinto I, Scala G, Palmieri C. Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. Leukemia 2016; 30:2419-2422. [PMID: 27568521 PMCID: PMC5155031 DOI: 10.1038/leu.2016.245] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- S Mimmi
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - E Vecchio
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - E Iaccino
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - M Rossi
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - A Lupia
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - F Albano
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - F Chiurazzi
- Department of Clinical Medicine, University 'Federico II' of Naples, Naples, Italy
| | - G Fiume
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - A Pisano
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - S Ceglia
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - M Pontoriero
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - G Golino
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - P Tassone
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - I Quinto
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - G Scala
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| | - C Palmieri
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy
| |
Collapse
|
17
|
Migliaccio N, Palmieri C, Ruggiero I, Fiume G, Martucci NM, Scala I, Quinto I, Scala G, Lamberti A, Arcari P. B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy. Cancer Cell Int 2015; 15:50. [PMID: 25983658 PMCID: PMC4433068 DOI: 10.1186/s12935-015-0202-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Accepted: 04/28/2015] [Indexed: 02/02/2023] Open
Abstract
Background Despite the clinical response of conventional anticancer therapy, including chemotherapeutic treatments, radiation therapy and corticosteroids, tumorigenic B-cell lymphomas show an incomplete response to clinical practices that result in a minimal residual disease (MRD) where few residual neoplastic cells undetected in vivo, replenish the cancer cell reservoir. This scenario, which is also shared with other cancer diseases, requires the development of strategies to advance in novel, selective targeting toward the tumorigenic cells that survive to the anticancer agents. Methods Here, we have taken advantage of the therapeutic properties of an idiotype specific peptide (pA20-36) that bind specifically to murine B-lymphoma cells in the setting of an anti cancer strategy, based on the selected delivery of electrostatic-based complex, peptide-siRNA. To this end, two engineered, arginine rich, peptides that included the pA20-36 targeting sequence were designed to bind fluorescent-labelled siRNA. One peptide presented 9 Arg at the C-terminal of pA20-36 whereas the other included 5 Arg at the N- and C-terminus, respectively. Results Compared to the control and random peptide-siRNA complexes, both pA20-36-siRNA complexes were endowed with the selective delivering of fluorescent-labelled siRNA toward the A20 murine B-cell lymphoma, as evaluated by cytofluorimetry and confocal microscopy, whereas fluorescent-labelled siRNA alone was not internalized in the selected cells. Compared to peptide controls, the use of the modified pA20-36 peptides complexed with siRNA anti-GAPDH and anti-Bcl2 showed a down-regulation in the expression levels of the corresponding genes. Conclusions Peptide-siRNA complex can be suitable tool for both selective peptide-driven cell targeting and gene silencing. In this setting, the improvement of this strategy is expected to provide a safe and non-invasive approach for the delivery of therapeutic molecules.
Collapse
Affiliation(s)
- Nunzia Migliaccio
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Camillo Palmieri
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Immacolata Ruggiero
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Giuseppe Fiume
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Nicola M Martucci
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Iris Scala
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Giuseppe Scala
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Annalisa Lamberti
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Paolo Arcari
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy ; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini, I-80131 Naples, Italy
| |
Collapse
|
18
|
Martucci NM, Rea I, Ruggiero I, Terracciano M, De Stefano L, Migliaccio N, Palmieri C, Scala G, Arcari P, Rendina I, Lamberti A. A new strategy for label-free detection of lymphoma cancer cells. BIOMEDICAL OPTICS EXPRESS 2015; 6:1353-1362. [PMID: 25909019 PMCID: PMC4399674 DOI: 10.1364/boe.6.001353] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Revised: 01/26/2015] [Accepted: 02/23/2015] [Indexed: 06/01/2023]
Abstract
In this paper, a new strategy for highly selective and sensitive direct detection of lymphoma cells by exploiting the interaction between a peptide and its B-cell receptor, has been evaluated. In particular, an idiotype peptide, able to specifically bind the B-cell receptor of A20 cells in mice engrafted with A20 lymphoma, has been used as molecular probe. The new detection technique has been demonstrated on a planar crystalline silicon chip. Coverage of 85% of silicon surface and detection efficiency of 8.5 × 10(-3) cells/μm(2) were obtained. The recognition strategy promises to extend its application in studying the interaction between ligands and their cell-surface receptors.
Collapse
Affiliation(s)
- Nicola M. Martucci
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples,
Italy
| | - Ilaria Rea
- Institute for Microelectronics and Microsystems, National Council of Research, Via P. Castellino 111, 80131 Naples,
Italy
| | - Immacolata Ruggiero
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples,
Italy
| | - Monica Terracciano
- Institute for Microelectronics and Microsystems, National Council of Research, Via P. Castellino 111, 80131 Naples,
Italy
- Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples,
Italy
| | - Luca De Stefano
- Institute for Microelectronics and Microsystems, National Council of Research, Via P. Castellino 111, 80131 Naples,
Italy
| | - Nunzia Migliaccio
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples,
Italy
| | - Camillo Palmieri
- Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Viale Europa, 88100 Germaneto, Catanzaro,
Italy
| | - Giuseppe Scala
- Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Viale Europa, 88100 Germaneto, Catanzaro,
Italy
| | - Paolo Arcari
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples,
Italy
| | - Ivo Rendina
- Institute for Microelectronics and Microsystems, National Council of Research, Via P. Castellino 111, 80131 Naples,
Italy
| | - Annalisa Lamberti
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples,
Italy
| |
Collapse
|
19
|
Loureiro A, Bernardes GJL, Shimanovich U, Sárria MP, Nogueira E, Preto A, Gomes AC, Cavaco-Paulo A. Folic acid-tagged protein nanoemulsions loaded with CORM-2 enhance the survival of mice bearing subcutaneous A20 lymphoma tumors. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 11:1077-83. [PMID: 25791804 DOI: 10.1016/j.nano.2015.02.022] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 02/20/2015] [Accepted: 02/24/2015] [Indexed: 12/20/2022]
Abstract
UNLABELLED Folic Acid (FA)-tagged protein nanoemulsions were found to be preferentially internalized on B-cell lymphoma cell line (A20 cell line), which, for the first time, is reported to express folate receptor (FR)-alpha. Carbon monoxide releasing molecule-2 (CORM-2) was incorporated in the oil phase of the initial formulation. FA-functionalized nanoemulsions loaded with CORM-2 exhibited a considerable antitumor effect and an increased survival of BALB/c mice bearing subcutaneous A20 lymphoma tumors. The developed nanoemulsions also demonstrated to be well tolerated by these immunocompetent mice. Thus, the results obtained in this study demonstrate that FA-tagged protein nanoemulsions can be successfully used in cancer therapy, with the important ability to delivery drugs intracellularly. FROM THE CLINICAL EDITOR In this research, the authors developed folic acid tagged nanoemulsions containing a carbon monoxide releasing protein molecule for targeted cancer cell treatment. In-vitro and in-vivo experiments showed efficacy against B-cell lymphoma cells. The same nanocarrier platform could be applied to other tumor cells expressing folate receptors on the cell surface.
Collapse
Affiliation(s)
- Ana Loureiro
- CEB-Centre of Biological Engineering, University of Minho, Campus of Gualtar, Braga, Portugal; CBMA (Centre of Molecular and Environmental Biology), University of Minho, Campus of Gualtar, Braga, Portugal
| | - Gonçalo J L Bernardes
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, United Kingdom; Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.
| | - Ulyana Shimanovich
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, United Kingdom
| | - Marisa P Sárria
- CEB-Centre of Biological Engineering, University of Minho, Campus of Gualtar, Braga, Portugal; CBMA (Centre of Molecular and Environmental Biology), University of Minho, Campus of Gualtar, Braga, Portugal
| | - Eugénia Nogueira
- CEB-Centre of Biological Engineering, University of Minho, Campus of Gualtar, Braga, Portugal; CBMA (Centre of Molecular and Environmental Biology), University of Minho, Campus of Gualtar, Braga, Portugal
| | - Ana Preto
- CBMA (Centre of Molecular and Environmental Biology), University of Minho, Campus of Gualtar, Braga, Portugal
| | - Andreia C Gomes
- CBMA (Centre of Molecular and Environmental Biology), University of Minho, Campus of Gualtar, Braga, Portugal
| | - Artur Cavaco-Paulo
- CEB-Centre of Biological Engineering, University of Minho, Campus of Gualtar, Braga, Portugal.
| |
Collapse
|
20
|
Naahidi S, Wang Y, Zhang M, Wang R, Jafari M, Yuan Y, Dixon B, Chen P. Evaluation of Biocompatibility of the AC8 Peptide and Its Potential Use as a Drug Carrier. Mol Pharm 2014; 11:3409-20. [PMID: 25055061 DOI: 10.1021/mp5001185] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Sheva Naahidi
- Department
of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
- Waterloo
Institute for Nanotechnology, University of Waterloo, 200 University
Avenue West, Waterloo, Ontario N2L 3G1, Canada
| | - Yujie Wang
- Department
of Pharmacy, Shanghai Third People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201999, China
| | - Man Zhang
- Department
of Pharmacy, Shanghai Third People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201999, China
| | - Rong Wang
- Department
of Pharmacy, Shanghai Third People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201999, China
| | - Mousa Jafari
- Department
of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
- Waterloo
Institute for Nanotechnology, University of Waterloo, 200 University
Avenue West, Waterloo, Ontario N2L 3G1, Canada
| | - Yongfang Yuan
- Department
of Pharmacy, Shanghai Third People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201999, China
| | - Brian Dixon
- Department
of Biology, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
| | - P. Chen
- Department
of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
- Waterloo
Institute for Nanotechnology, University of Waterloo, 200 University
Avenue West, Waterloo, Ontario N2L 3G1, Canada
| |
Collapse
|
21
|
Tuccillo FM, Palmieri C, Fiume G, de Laurentiis A, Schiavone M, Falcone C, Iaccino E, Galandrini R, Capuano C, Santoni A, D'Armiento FP, Arra C, Barbieri A, Dal Piaz F, Venzon D, Bonelli P, Buonaguro FM, Scala I, Mallardo M, Quinto I, Scala G. Cancer-associated CD43 glycoforms as target of immunotherapy. Mol Cancer Ther 2013; 13:752-62. [PMID: 24356816 DOI: 10.1158/1535-7163.mct-13-0651] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
CD43 is a sialoglycosylated membrane protein that is involved in cell proliferation and differentiation. CD43 glycoforms that are recognized by the UN1 monoclonal antibody (mAb) were expressed in lymphoblastoid T-cell lines and solid tumors, such as breast, colon, gastric, and squamous cell lung carcinomas, while unexpressed in the normal counterparts. The cancer association of UN1/CD43 epitope suggested the possibility to use the UN1 mAb for tumor diagnosis and therapy. In this study, we show that the UN1 mAb was endowed with antitumor activity in vivo because its passive transfer inhibited the growth of UN1-positive HPB-ALL lymphoblastoid T cells in mice. Furthermore, we demonstrate that tumor inhibition was due to UN1 mAb-dependent natural killer-mediated cytotoxicity. By screening a phage-displayed random peptide library, we identified the phagotope 2/165 as a mimotope of the UN1 antigen, as it harbored a peptide sequence that was specifically recognized by the UN1 mAb and inhibited the binding of the UN1 mAb to UN1-positive tumor cells. On the basis of sequence homology with the extracellular region of CD43 (amino acids 64 to 83), the 2/165 peptide sequence was likely mimicking the protein core of the UN1/CD43 epitope. When used as vaccine in mice, the 2/165 phagotope raised antibodies against the UN1/CD43 antigen, indicating that the 2/165 phagotope mimicked the UN1 antigen structure, and could represent a novel immunogen for cancer immunotherapy. These findings support the feasibility of using monoclonal antibodies to identify cancer-associated mimotopes for immunotherapy.
Collapse
Affiliation(s)
- Franca Maria Tuccillo
- Corresponding Authors: Franca Maria Tuccillo, Laboratory of Molecular Biology and Viral Oncogenesis, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale", IRCCS, via Mariano Semmola, 80131, Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Rêgo MJBM, Silva LPBG, Medeiros JKG, Figueiredo RCBQ, Alves-Júnior S, Beltrão EIC. Con A conjugated to Europium(III) cryptate as a new histological tool for prostate cancer investigation using confocal microscopy. Biotech Histochem 2013; 89:321-6. [PMID: 24160413 DOI: 10.3109/10520295.2013.846479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Lectins are carbohydrate recognition proteins that can be used as probes to reveal the glycosylation state of cells. They frequently have been used for diagnostic and prognostic cancer studies. For fluorescence based analysis, lectins commonly are conjugated to fluorescein isothiocyanate (Con A-FITC); however, this molecule loses its fluorescence quickly. We conjugated Europium cryptate to Con A (Con A-cryp-Eu) for use as a histochemical luminescent probe to recognize glucose/mannose residues in benign prostatic hyperplasia and prostatic carcinoma tissues, and used confocal microscopy instead of commercial Con A-FITC. Tissues were treated with Evans blue to suppress intrinsic tissue fluorescence before incubation with Con A-cryp-Eu or Con A-FITC. Con A-cryp-Eu exhibited hemagglutinating activity. Con A-cryp-Eu showed the same binding pattern as Con A-FITC in prostate stroma and gland cells. Staining was strong in benign prostate hyperplasia and prostate carcinoma tissues. Con A-cryp-Eu probe stained glucose/mannose residues in prostatic carcinoma more intensely than Con A-FITC. Furthermore, staining with Con A-cryp-Eu showed greater fluorescence intensity than Con A-FITC and the emission of Con A-cryp-Eu was more stable than the Con A-FITC for seven days under the same storage conditions. Maintenance of the luminescent properties and the binding pattern of Con A-cryp-Eu favor its use as an auxiliary histochemistry probe for prostatic tissue studies.
Collapse
Affiliation(s)
- M J B M Rêgo
- Keizo Asami Immunopathology Laboratory, University Federal of Pernambuco
| | | | | | | | | | | |
Collapse
|
23
|
Galand C, Donnou S, Molina TJ, Fridman WH, Fisson S, Sautès-Fridman C. Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Front Immunol 2012; 3:98. [PMID: 22566974 PMCID: PMC3343266 DOI: 10.3389/fimmu.2012.00098] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2012] [Accepted: 04/14/2012] [Indexed: 12/18/2022] Open
Abstract
Diffuse large B-cell lymphomas (DLBCLs) are heterogeneous diseases growing either in nodal or extranodal locations including the central nervous system. One key issue is to decipher the prognostic value of immune cells infiltrating these tumors as DLBCLs developing in sanctuaries are more aggressive than nodal DLCBLs. Here, we summarize available data from the literature regarding the prognostic values of the different immune cell types found in these two types of human primary tumors (i.e., nodal vs brain). In nodal DLBCLs, memory T-cells and dendritic cells (DCs) densities are of good prognostic value whereas the influence of regulatory T-cells (Tregs) is less clear, in accordance with other types of cancers. Data for primary central nervous system lymphomas are very sparse for these cell types. By contrast, CD8+ cytotoxic T-cells seem to be of poor prognosis in either location. Their presence is linked to a loss of MHC expression providing a possible immune escape mechanism for these tumors. Clearly, tumor-associated macrophages are not associated to a significant prognostic value even in the brain where they highly infiltrate the tumor. Animal models indicate some specific features of lymphoma developing in sanctuaries by comparison to splenic location, with a higher infiltration of Tregs and less DCs, most likely reflecting the immunosuppressive context of these organs. All these informations illustrate the high impact of the immune system on patient outcome, encourage the pursuit of the immune environment’s analysis and of immunotherapeutic approaches.
Collapse
Affiliation(s)
- Claire Galand
- INSERM, UMRS872, Centre de Recherche des Cordeliers Paris, France
| | | | | | | | | | | |
Collapse
|
24
|
Galasso O, Iaccino E, Gallelli L, Perrotta I, Conforti F, Donato G, Gasparini G. Collagen type V polymorphism in spontaneous quadriceps tendon ruptures. Orthopedics 2012; 35:e580-4. [PMID: 22495864 DOI: 10.3928/01477447-20120327-31] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Spontaneous simultaneous bilateral quadriceps tendon rupture is associated with multiple medical conditions and pharmacological treatments; however, identifying prior risk factors is impossible in most cases. Achilles tendon and anterior cruciate ligament ruptures are associated with collagen, type V, alpha 1 (COL5A1) polymorphism. This genetic variant may be implicated quadriceps tendon rupture. The COL5A1 encodes the protein for pro-α1 chains of the low-abundance heterotrimeric type V collagen. In most noncartilaginous tissues, type V collagen is a quantitatively minor component of type I collagen that has been implicated in the regulation of the size and configuration of type I collagen fibrils. The functional significance of COL5A1 polymorphism in relation to type V collagen expression or activity has not been determined.This article describes a patient with COL5A1 polymorphism and spontaneous simultaneous quadriceps tendon rupture. However, genetic and histologic studies performed on blood and tendon tissues and 3 consecutive sex- and age-matched controls showed a statistically significant reduction in collagen type V expression and an alteration in collagen structure in the tendon. These findings might explain the pathomechanisms of spontaneous tendon ruptures associated with COL5A1 polymorphism.
Collapse
Affiliation(s)
- Olimpio Galasso
- Department of Orthopaedic and Trauma Surgery, University Magna Græcia of Catanzaro, School of Medicine, Catanzaro, Italy.
| | | | | | | | | | | | | |
Collapse
|
25
|
Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol 2012; 2012:701704. [PMID: 22400032 PMCID: PMC3287022 DOI: 10.1155/2012/701704] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2011] [Accepted: 10/21/2011] [Indexed: 12/21/2022] Open
Abstract
Human B-cell lymphomas, the fourth most common hematologic malignancy, are currently the subject of extensive research. The limited accessibility of biopsies, the heterogeneity among patients, and the subtypes of lymphomas have necessitated the development of animal models to decipher immune escape mechanisms and design new therapies. Here, we summarize the cell lines and murine models used to study lymphomagenesis, the lymphoma microenvironment, and the efficacy of new therapies. These data allow us to understand the role of the immune system in the fight against tumors. Exploring the advantages and limitations of immunocompetent versus immunodeficient models improves our understanding of the molecular and cellular mechanisms of tumor genesis and development as well as the fundamental processes governing the interaction of tumors and their host tissues. We posit that these basic preclinical investigations will open up new and promising approaches to designing better therapies.
Collapse
|
26
|
Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig HH, Mertelsmann R, Trepel M. Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. Int J Cancer 2011; 131:E10-20. [PMID: 21953178 DOI: 10.1002/ijc.26464] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Accepted: 09/12/2011] [Indexed: 11/06/2022]
Abstract
Receptor-targeted therapies have become standard in the treatment of various lymphomas. In view of its unparalleled specificity for the malignant B-cell clone, the B-cell receptor (BCR) on B cell lymphoma cells is a potential therapeutic target. We have used two BCR epitope mimicking peptides binding to the Burkitt's lymphoma cell lines CA46 and SUP-B8. We proved their functionality by demonstrating calcium flux and BCR-mediated endocytosis upon peptide receptor binding. Toxicity experiments in vitro via cross-linking of the BCR with tetramerized epitope mimics lead to apoptosis in both cell lines but was far more effective in SUP-B8 cells. We established a SUP-B8-based disseminated Burkitt's lymphoma model in NOD/SCID mice. Treatment of tumor-bearing mice with tetramerized epitope mimics had significant anti-tumor effects in vivo. We conclude that peptide-mediated, BCR-targeted therapy is a promising approach which may be explored and further developed for application in highly aggressive lymphoma.
Collapse
Affiliation(s)
- Claudia Wehr
- Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
The inhibitor of Bruton tyrosine kinase γ (IBtkγ) is a negative regulator of the Bruton tyrosine kinase (Btk), which plays a major role in B-cell differentiation; however, the mechanisms of IBtkγ-mediated regulation of Btk are unknown. Here we report that B-cell receptor (BCR) triggering caused serine-phosphorylation of IBtkγ at protein kinase C consensus sites and dissociation from Btk. By liquid chromatography and mass-mass spectrometry and functional analysis, we identified IBtkγ-S87 and -S90 as the critical amino acid residues that regulate the IBtkγ binding affinity to Btk. Consistently, the mutants IBtkγ carrying S87A and S90A mutations bound constitutively to Btk and down-regulated Ca(2+) fluxes and NF-κB activation on BCR triggering. Accordingly, spleen B cells from Ibtkγ(-/-) mice showed an increased activation of Btk, as evaluated by Y551-phosphorylation and sustained Ca(2+) mobilization on BCR engagement. These findings identify a novel pathway of Btk regulation via protein kinase C phosphorylation of IBtkγ.
Collapse
|
28
|
De Angelis F, Pujia A, Falcone C, Iaccino E, Palmieri C, Liberale C, Mecarini F, Candeloro P, Luberto L, de Laurentiis A, Das G, Scala G, Di Fabrizio E. Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context. NANOSCALE 2010; 2:2230-2236. [PMID: 20835434 DOI: 10.1039/c0nr00161a] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Multitasking nanoparticles are gaining great attention for smart drug delivery systems. The exploration of the nano-scale opens new concrete opportunities for revealing new properties and undiscovered cell-particle interactions. Here we present a biodegradable nanoporous silicon nanoparticle that can be successfully employed for in vivo targeted drug delivery and sustained release. The bare nanoporous nanocarriers can be accurately designed and fabricated with an effective control of porosity, surface chemistry and particle size, up to a few nm. The proposed nanoparticles exhibit several remarkable features including high payload, biodegradability, no toxicity, and multiple loading in water without the need of additional chemical reagents at room temperature. The targeting strategy is based on phage display technology that was successfully used to discover cell surface binding peptide for murine B lymphoma A20 cell line. The peptide used in combination with the nanoporous nanoparticles allows an efficient in vivo targeting, a sustained release and a sensible therapeutic effect.
Collapse
Affiliation(s)
- F De Angelis
- Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|